Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Helsinki – page 12

400 clinical trials in Helsinki, Finland across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Helsinki at a glance
400
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

400 trials in Helsinki

Open in trial search

Plasma cell myeloma refractory

Recruiting

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

VEXAS syndrome

Recruiting

Study of Azacitidine Treatment in Patients with VEXAS Syndrome

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Rigshospitalet

Critical illness

Recruiting

Study of Epoetin Alfa for Critically Ill Patients with Traumatic Injury

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:University College Dublin

Triple negative breast cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Chronic lymphocytic leukaemia+1

Recruiting

Long-Term Safety Study of BCMACP03, BCN-CP01, and 19CP02 for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, CLL, SLL, or Multiple Myeloma

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:BCMACP03
  • Sponsor:Galapagos

Plasma cell myeloma refractory

Recruiting

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Cardiac failure

Recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Hormone-refractory prostate cancer+2

Recruiting

Study on the Effectiveness of Abiraterone, Capivasertib, and Enzalutamide in Patients with Metastatic Prostate Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Karolinska Institutet

Neoplasm malignant

Recruiting

Study on 68Ga-FAPI-46 for Imaging Pancreatic, Stomach, Bile Duct, and Ovarian Cancers in Patients with Solid Tumors

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Karolinska University Hospital

Myocarditis

Recruiting

Study on the Safety and Effectiveness of Methylprednisolone Sodium Succinate and Sodium Chloride for Patients with Severe Cardiac Inflammation

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:ASST Grande Ospedale Metropolitano Niguarda

Acute lymphocytic leukaemia+4

Recruiting

Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years
  • Substances:Trametinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Mechanical ventilation+2

Recruiting

Study on Early Sedation with Dexmedetomidine vs. Placebo for Older Critically Ill Patients on Ventilators

Registered drug
Countries:FinlandFinland
  • Participants:65+ years
  • Sponsor:Monash University

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Helsinki

What the registry says about research in the country

01 Infectious Disease Prevention

Clinical trials focusing on vaccine development against various infectious diseases, including studies of RSV, meningococcal, and influenza vaccines in different age groups.

  • Respiratory Virus Vaccines
  • Bacterial Disease Prevention
  • Immune Response Studies

Research emphasizes safety, immunogenicity, and efficacy in diverse populations from infants to older adults.

02 Neurological Conditions

Innovative research in stroke treatment and cerebral vasculature disorders, including studies on acute ischemic stroke interventions and vasoconstriction syndrome management.

  • Stroke Therapeutics
  • Dementia Prevention
  • Vascular Disorders

Trials combine therapeutic interventions with lifestyle modifications to improve patient outcomes.

03 Metabolic Disorders

Studies addressing obesity management through novel therapeutic approaches combined with lifestyle interventions, focusing on weight-related complications.

  • Weight Management
  • Metabolic Health
  • Lifestyle Interventions

Research emphasizes comprehensive treatment strategies for metabolic health improvement.

04 Oncology Research

Advanced studies in acute myeloid leukemia treatment, investigating combination therapies for patients unsuitable for intensive chemotherapy.

  • Blood Cancer Treatments
  • Targeted Therapies
  • Novel Drug Combinations

Focusing on personalized treatment approaches for specific genetic mutations.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.